Daily Anesthesiology Research Analysis

The perioperative management of patients using glucagon-like peptide 1 receptor agonists remains a topic of debate. While several multisociety statements have been published recently, the recommendations vary significantly in terms of medication management and preoperative fasting protocols for these patients. This document represents a multidisciplinary consensus statement led by the Society for Perioperative Assessment and Quality Improvement (SPAQI). It provides updated recommendations based on a modified Delphi process and supported by a systematic review of the current literature. The recommendations address management of the glucagon-like peptide 1 receptor agonists perioperatively, and preoperative fasting times for both solids and liquids. SYSTEMATIC REVIEW PROTOCOL: PROSPERO (CRD42023438624).

RATIONALE: The significance of the Recruitment to Inflation (R/I) ratio in identifying PEEP recruiters in patients undergoing ultra-protective lung ventilation during venovenous ECMO is not well established. OBJECTIVES: To compare the concordance of the R/I ratio and Electrical Impedance Tomography (EIT) in determining optimum PEEP settings in severe ARDS patients on ECMO and ventilated with very low tidal volumes. METHODS: Initially, a low-flow insufflation was performed to detect and measure the airway opening pressure (AOP). Subsequently, the R/I ratio was calculated from PEEP 15-5 cmH MAIN RESULTS: Among 54 ECMO patients (tidal volume: 4.8 [3.0-6.0] mL/kg), 13 (24%) exhibited an airway opening pressure (AOP) of 11 (8-14) cmH CONCLUSION: The R/I ratio is feasible during ultra-protective ventilation and provides valuable indications for guiding PEEP titration. Specifically, an R/I ratio > 0.34 may help identify patients likely to benefit from further individualized PEEP optimization using EIT. In contrast, when the R/I ratio is ≤ 0.34, a moderate PEEP level (8-10 cmH₂O) may suffice.

BACKGROUND: Although neostigmine has been traditionally used for neuromuscular blockade reversal in thoracic surgery, incomplete reversal and potential pulmonary complications remain concerns. However, we did not preclude its clinical use. In contrast, sugammadex offers more predictable recovery of neuromuscular function with a superior safety profile. This study aims to compare the efficacy of sugammadex versus neostigmine in improving postoperative recovery outcomes. METHODS: This study is a prospective, randomized, double-blind trial. Patients above 65 years old undergoing video-assisted thoracoscopic lobectomy were randomly assigned to receive either sugammadex (2 mg/kg) or neostigmine (0.04 mg/kg) with atropine for neuromuscular block reversal after T2 appearance on TOF. The primary outcome was the quality of recovery at postoperative day (POD) 1, assessed by the QoR-15 questionnaire. Secondary outcomes included extubation time, PACU stay, incidence of hypoxaemia, PRNB, and postoperative pulmonary complications (PPCs). RESULTS: Data analysis included 77 patients (39 in Group S and 38 in Group N). The QoR-15 scores were significantly higher in the sugammadex group at day 1 (125 vs. 122, P < 0.001). Sugammadex significantly reduced extubation time (18 vs. 27.5 min, P = 0.001) and PACU stay (52 vs. 62 min, P = 0.001). Hypoxaemia (28% vs. 53%, P = 0.029) and PRNB (5% vs. 24%, P = 0.020) were less frequent in the sugammadex group. The sugammadex group had fewer PPCs, the difference was not statistically significant (26% vs. 45%, P = 0.079). CONCLUSIONS: For elderly patients receiving VATS lobectomy, sugammadex is beneficial for acute recovery except PONV up to POD1 recovery quality mainly in ease of breath, eating, resting but not in postoperative outcomes over one month. TRIAL REGISTRATION: Retrospectively registered, Chinese Clinical Trial Registry, ChiCTR2400089863(Date:18/09/2024).